Abbott (NYSE:ABT) Stock: Higher Earnings Outlook and Fresh Libre Data Land in One Season
Abbott (NYSE:ABT) Stock: Higher Earnings Outlook and Fresh Libre Data Land in One Season kalkine.ca
Covered in this story
What has happened since
- Abbott Laboratories is down 2.1% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Abbott Laboratories
- Citi: $101 → $112 by Jul 2027 via GuruFocus
- Piper Sandler: $101 → $118 by Jul 2027 · Overweight via GuruFocus
- Wells Fargo: $101 → $112 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 49 stories mentioning Abbott Laboratories, the earliest published 17 Apr 2026.
Summary aggregated from kalkine.ca's public RSS feed. The full reporting belongs to kalkine.ca — please read it on their site.